Tenosynovial Giant Cell Tumor: New Approaches to Enhance Patient’s Functionality and Quality of Life
October 24, 2019
April 24, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Term of Offering
This activity was released on October 24, 2019 and is valid for 6 months. Requests for credit must be made no later than April 24, 2020.
After completing this activity, the participant should be better able to:
- Discuss the signs and symptoms of localized and diffuse types of TGCT, as well as appropriate tests to confirm a diagnosis
- Identify patients with TGCT who are likely versus not likely to benefit from surgery
- Describe the mechanism of action, benefits and adverse events of new and emerging pharmacologic treatment options for TGCT patients who are symptomatic and not candidates for surgery
The educational design of this activity addresses the needs of oncologists, orthopedic surgeons, radiologists, sports medicine physicians, and other HCPs involved in the identification and management/treatment of patients with TGCT, including NPs, PAs, and nurses.
Statement of Need/Program Overview
Up until recently, the standard of care for tenosynovial giant cell tumor (TGCT) was surgery. However, often, surgery is technically challenging and fails to resolve pain and improve disability in those who are affected. The findings that TGCT is driven by CSF1 overexpression in neoplastic synovial cells have led scientist to investigate systemic treatment approaches. Recently, the US Food and Drug Administration approved one such agent, pexidartinib. The availability of systemic agents can drastically change the care of patients with this debilitating condition and who are not candidates for surgery. The standard of care of TGCT patients is changing, requiring that clinicians keep up to date with the most current and emerging evidence-based therapies, and become more knowledgeable about the signs and symptoms of the condition.
To ensure that participants benefit from the latest information on the management of TGCT, the timing of this activity series is aligned with the Connective Tissue Oncology Society (CTOS) annual meeting, the Musculoskeletal Tumor Society (MTS) annual meeting, and the National Organization for Rare Disorders’ (NORD) Rare Diseases and Orphan Products Breakthrough Summit. This first CME session will help on defining the type and prevalence of TGCT, the risks inherent to surgery and new and emerging options. A patient with TCGT will describe his journey through care from his experience with diagnostic delays, referral, and quality of life.
Estimated Time to Complete
This activity should take approximately 1 hour to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|John H. Healey, MD |
Chief, Orthopaedic Surgery
Memorial Sloan Kettering Cancer Center
|Consultant/Independent Contractor: Daiichi Sankyo Honoraria: Daiichi Sankyo |
Speaker’s Bureau: PlatformQ
Advisory Board: Daiichi Sankyo Publication Advisory Board
|William D. Tap, MD |
Chief, Sarcoma Medical Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
|Consultant/Independent Contractor: Adaptimmune, Agios Pharmaceuticals, Blueprint, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Loxo, NannoCarrier, Novartis, Plexxikon Pharmaceuticals |
Honoraria: Adaptimmune, Agios Pharmaceuticals, Blueprint, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Loxo, NannoCarrier, Novartis
Advisory Board: Adaptimmune, Agios Pharmaceuticals, Blueprint, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Loxo, NannoCarrier, Novartis, Plexxikon Pharmaceuticals
Stock Shareholder: Atropos Therapeutics, Certis Oncology Solutions
Other/Royalty: Companion Diagnostics for CDK4 inhibitors
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Planner or Manager||Reported Financial Relationship|
|Kristen Neuhaus||Nothing to disclose|
|Lindsay Borvansky||Nothing to disclose|
|Andrea Funk||Nothing to disclose|
|Liddy Knight||Nothing to disclose|
|Ashley Cann||Nothing to disclose|
|Laura Engles-Horton||Nothing to disclose|
|Alissa Yost||Nothing to disclose|
Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please send content inquiries to: firstname.lastname@example.org.
For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@OMedLive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting email@example.com with the subject line “Data Request”